
Immatics NV (IMTX) Stock Forecast & Price Target
Immatics NV (IMTX) Analyst Ratings
Bulls say
Immatics NV presents a positive outlook largely due to the promising performance of its anzu-cel asset, particularly in the ongoing Phase 3 SUPRAME study, which aims to demonstrate a meaningful increase in progression-free survival (PFS) over control. The company's innovative ACTengine platform enhances manufacturing logistics, achieving a notable 98% success rate and a swift 14-day turnaround for product release, thereby positioning it competitively within the market. Additionally, the recent RMAT designation from the FDA for anzu-cel underscores its potential in addressing high unmet medical needs within the lucrative market of metastatic cancers, emphasizing the strategic growth opportunities for Immatics in the near future.
Bears say
The financial outlook for Immatics NV is negative due to underwhelming clinical data presented for their lead candidate, Brenetafusp, which achieved only an 11% overall response rate and a 56% disease control rate in a key patient segment, raising concerns about its commercial viability. Additionally, the company faces multifaceted risks, including potential setbacks in research and development, regulatory challenges, and competitive pressures that could further hinder product sales and financial projections. Finally, anticipated downward revisions to risk-adjusted projections cast uncertainty over the company's valuation, with a downside scenario suggesting a valuation as low as $3 per share if key milestones are not met.
This aggregate rating is based on analysts' research of Immatics NV and is not a guaranteed prediction by Public.com or investment advice.
Immatics NV (IMTX) Analyst Forecast & Price Prediction
Start investing in Immatics NV (IMTX)
Order type
Buy in
Order amount
Est. shares
0 shares